MODERN APPROACHES TO NEUROPROTECTION IN TRAUMATIC BRAIN INJURIES, CEREBROVASCULAR DISEASES, AND COGNITIVE IMPAIRMENTS FOLLOWING ANTITUMOR THERAPY

Fedir  Hladkykh; Tetyana  Liadova; Mariia  Matvieienko; Olha  Karafulidi; Pavlo  Zhuchenko

doi:10.21272/eumj.2025;13(2):333-351

Fedir Hladkykh V. N. Karazin Kharkiv National University of the Ministry of Education and Science of Ukraine, Kharkiv, Ukraine; State Organization ''Grigoriev Institute for medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine'', Kharkiv, Ukraine https://orcid.org/0000-0001-7924-4048
Tetyana Liadova V. N. Karazin Kharkiv National University of the Ministry of Education and Science of Ukraine, Kharkiv, Ukraine https://orcid.org/0000-0002-5892-2599
Mariia Matvieienko V. N. Karazin Kharkiv National University of the Ministry of Education and Science of Ukraine, Kharkiv, Ukraine https://orcid.org/0000-0002-0388-138X
Olha Karafulidi Municipal Non-Profit Enterprise "Kharkiv City Clinical Hospital of Emergency Aid named by prof. O.I. Meshchaninov" of the Kharkiv City Council, Kharkiv, Ukraine https://orcid.org/0009-0008-4669-6708
Pavlo Zhuchenko Vinnytsia National Pyrogov Memorial Medical University of the Ministry of Health of Ukraine, Vinnytsia, Ukraine https://orcid.org/0000-0003-3295-8582

DOI: https://doi.org/10.21272/eumj.2025;13(2):333-351

Keywords: neuroprotection, traumatic brain injury, cerebrovascular diseases, neuroinflammation, cognitive impairments, cognitive-behavioral therapy

Abstract

Background. With the increase in life expectancy, the number of patients with neurodegenerative diseases, particularly dementia, is rising. Concurrently, improving survival rates in cancer patients is accompanied by chemotherapy side effects, including cognitive impairments. Approximately 70% of patients after chemotherapy experience memory, attention, and multitasking problems, significantly affecting their quality of life.

Objective of the study was to characterize contemporary approaches to neuroprotection in traumatic brain injuries, cerebrovascular diseases, and cognitive impairments following oncological treatment.

Materials and Methods. Publications were selected from PubMed, Clinical Key Elsevier, Cochrane Library, eBook Business Collection, and Google Scholar, focusing on neuroprotection strategies for traumatic brain injury, cerebrovascular diseases, and cognitive impairments after cancer therapy. The review was prepared following PRISMA guidelines.

Results. Neuroprotection in neurodegenerative and cerebrovascular diseases focuses on reducing oxidative stress, improving mitochondrial function, regulating excitotoxicity, and controlling neuroinflammation. A comprehensive approach that considers the neurovascular unit helps develop new therapeutic strategies for brain protection. Chemotherapy induces cognitive impairments through microglia activation, oxidative stress, and changes in cerebrovascular function. Psychostimulants, antidepressants, and anti-inflammatory drugs may improve cognitive functions, though their effectiveness requires further research. Combined strategies, including physical activity, cognitive-behavioral therapy, and pharmacotherapy, have shown potential for improving cognitive recovery after cancer treatment.

Conclusions. Neurodegenerative diseases, ischemic stroke, and traumatic brain injury demand new therapeutic strategies. Cognitive impairments following chemotherapy require an integrated approach, combining psychopharmacology, cognitive-behavioral therapy, and physical activity.

Downloads

Download data is not yet available.

References

Arias-Sánchez RA, Torner L, Fenton Navarro B. Polyphenols and Neurodegenerative Diseases: Potential Effects and Mechanisms of Neuroprotection. Molecules. 2023 Jul 14;28(14):5415. https://doi.org/10.3390/molecules28145415. PMID: 37513286; PMCID: PMC10385962.

Nguyen LD, Ehrlich BE. Cellular mechanisms and treatments for chemobrain: insight from aging and neurodegenerative diseases. EMBO Mol Med. 2020 Jun 8;12(6):e12075. https://doi.org/10.15252/emmm.202012075. Epub 2020 Apr 29. PMID: 32346964; PMCID: PMC7278555.

Fernandez HR, Varma A, Flowers SA, Rebeck GW. Cancer Chemotherapy Related Cognitive Impairment and the Impact of the Alzheimer's Disease Risk Factor APOE. Cancers (Basel). 2020 Dec 19;12(12):3842. https://doi.org/10.3390/cancers12123842. PMID: 33352780; PMCID: PMC7766535.

Jang A, Petrova B, Cheong TC, Zawadzki ME, Jones JK, Culhane AJ, Shipley FB, Chiarle R, Wong ET, Kanarek N, Lehtinen MK. Choroid plexus-CSF-targeted antioxidant therapy protects the brain from toxicity of cancer chemotherapy. Neuron. 2022 Oct 19;110(20):3288-3301.e8. https://doi.org/10.1016/j.neuron.2022.08.009. Epub 2022 Sep 6. PMID: 36070751; PMCID: PMC9588748.

Gan L, Cookson MR, Petrucelli L, La Spada AR. Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci. 2018 Oct;21(10):1300-1309. https://doi.org/10.1038/s41593-018-0237-7. Epub 2018 Sep 26. PMID: 30258237; PMCID: PMC6278826.

Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs. 2017 Jun;26(6):735-739. https://doi.org/10.1080/13543784.2017.1323868. PMID: 28460541; PMCID: PMC5576861.

Guerreiro S, Privat AL, Bressac L, Toulorge D. CD38 in Neurodegeneration and Neuroinflammation. Cells. 2020 Feb 18;9(2):471. https://doi.org/10.3390/cells9020471. PMID: 32085567; PMCID: PMC7072759.

Aliev G. Pharmacological Approaches Targeting Brain Cell Survival in the Context of Neurodegeneration and Potential Treatment Strategies. Curr Neuropharmacol. 2019;17(3):198-200. https://doi.org/10.2174/1570159X17666181227163039. PMID: 30592253; PMCID: PMC6425073.

Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci. 2012;13(9):11753-11772. https://doi.org/10.3390/ijms130911753. Epub 2012 Sep 18. PMID: 23109881; PMCID: PMC3472773.

Lyden P, Buchan A, Boltze J, Fisher M; STAIR XI Consortium*. Top Priorities for Cerebroprotective Studies-A Paradigm Shift: Report From STAIR XI. Stroke. 2021 Aug;52(9):3063-3071. https://doi.org/10.1161/STROKEAHA.121.034947. Epub 2021 Jul 22. PMID: 34289707; PMCID: PMC8384700.

Chen H, Wu F, Yang P, Shao J, Chen Q, Zheng R. A meta-analysis of the effects of therapeutic hypothermia in adult patients with traumatic brain injury. Crit Care. 2019 Dec 5;23(1):396. https://doi.org/10.1186/s13054-019-2667-3. PMID: 31806001; PMCID: PMC6896404.

Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, Bragge P, Brazinova A, et al InTBIR Participants and Investigators. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017 Dec;16(12):987-1048. https://doi.org/10.1016/S1474-4422(17)30371-X. Epub 2017 Nov 6. PMID: 29122524.

Cooper DJ, Nichol A, Presneill J. Hypothermia for Intracranial Hypertension after Traumatic Brain Injury. N Engl J Med. 2016 Apr 7;374(14):1384. https://doi.org/10.1056/NEJMc1600339. PMID: 27050215.

Kövesdi E, Szabó-Meleg E, Abrahám IM. The Role of Estradiol in Traumatic Brain Injury: Mechanism and Treatment Potential. Int J Mol Sci. 2020 Dec 22;22(1):11. https://doi.org/10.3390/ijms22010011. PMID: 33374952; PMCID: PMC7792596.

Kincses ZT, Vecsei L. Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection. CNS Neurosci Ther. 2011;17(5):345-67. https://doi.org/10.1111/j.1755-5949.2010.00150.x. Epub 2010, 23 квітня. PMID: 20438581; PMCID: PMC6493808.

Sutherland BA, Minnerup J, Balami JS, Arba F, Buchan AM, Kleinschnitz C. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke. 2012 Jul;7(5):407-18. https://doi.org/10.1111/j.1747-4949.2012.00770.x. Epub 2012 Mar 6. PMID: 22394615.

Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008 Sep;55(3):363-89. https://doi.org/10.1016/j.neuropharm.2007.12.007. Epub 2008 Mar 4. PMID: 18308347; PMCID: PMC2631228.

Durukan A, Tatlisumak T. Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav. 2007 May;87(1):179-97. https://doi.org/10.1016/j.pbb.2007.04.015. Epub 2007 May 4. PMID: 17521716.

Zoppo GJ. The neurovascular unit in the setting of stroke. J Intern Med. 2010 Feb;267(2):156-71. https://doi.org/10.1111/j.1365-2796.2009.02199.x. PMID: 20175864; PMCID: PMC3001328.

Savitz SI, Baron JC, Fisher M; STAIR X Consortium. Stroke Treatment Academic Industry Roundtable X: Brain Cytoprotection Therapies in the Reperfusion Era. Stroke. 2019 Mar;50(4):1026–1031. https://doi.org/10.1161/STROKEAHA.118.023927. PMID: 31166683.

Bai J, Lyden PD. Revisiting cerebral postischemic reperfusion injury: new insights in understanding reperfusion failure, hemorrhage, and edema. Int J Stroke. 2015 Feb;10(2):143-52. https://doi.org/10.1111/ijs.12434. PMID: 25598025.

Globus MY, Ginsberg MD, Busto R. Excitotoxic index--a biochemical marker of selective vulnerability. Neurosci Lett. 1991 Jun 10;127(1):39-42. https://doi.org/10.1016/0304-3940(91)90889-2. PMID: 1679223.

Kirino T, Sano K. Selective vulnerability in the gerbil hippocampus following transient ischemia. Acta Neuropathol. 1984;62(3):201-8. https://doi.org/10.1007/BF00691853. PMID: 6695554.

Mabuchi T, Lucero J, Feng A, Koziol JA, del Zoppo GJ. Focal cerebral ischemia preferentially affects neurons distant from their neighboring microvessels. J Cereb Blood Flow Metab. 2005 Feb;25(2):257-66. https://doi.org/10.1038/sj.jcbfm.9600027. PMID: 15678127.

Lyden PD, Lamb J, Kothari S, Toossi S, Boitano P, Rajput PS. Differential effects of hypothermia on neurovascular unit determine protective or toxic results: Toward optimized therapeutic hypothermia. J Cereb Blood Flow Metab. 2019 Sep;39(9):1693-1709. https://doi.org/10.1177/0271678X18814614. Epub 2018 Nov 21. PMID: 30461327; PMCID: PMC6727141.

Rajput PS, Lamb J, Kothari S, Pereira B, Soetkamp D, Wang Y, Tang J, Van Eyk JE, Mullins ES, Lyden PD. Neuron-generated thrombin induces a protective astrocyte response via protease activated receptors. Glia. 2020 Feb;68(2):246-262. https://doi.org/10.1002/glia.23714. Epub 2019 Aug 27. PMID: 31453648; PMCID: PMC7391964.

Lu Y, Sareddy GR, Wang J, Zhang Q, Tang FL, Pratap UP, Tekmal RR, Vadlamudi RK, Brann DW. Neuron-Derived Estrogen Is Critical for Astrocyte Activation and Neuroprotection of the Ischemic Brain. J Neurosci. 2020 Sep 16;40(38):7355-7374. https://doi.org/10.1523/JNEUROSCI.0115-20.2020. Epub 2020 Aug 19. PMID: 32817249; PMCID: PMC7534920.

Wang J, Sareddy GR, Lu Y, Pratap UP, Tang F, Greene KM, Meyre PL, Tekmal RR, Vadlamudi RK, Brann DW. Astrocyte-Derived Estrogen Regulates Reactive Astrogliosis and is Neuroprotective following Ischemic Brain Injury. J Neurosci. 2020 Dec 9;40(50):9751-9771. https://doi.org/10.1523/JNEUROSCI.0888-20.2020. Epub 2020 Nov 6. PMID: 33158962; PMCID: PMC7726540.

Pitt J, Wilcox KC, Tortelli V, Diniz LP, Oliveira MS, Dobbins C, Yu XW, Nandamuri S, Gomes FCA, DiNunno N, Viola KL, De Felice FG, Ferreira ST, Klein WL. Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers. Mol Biol Cell. 2017 Oct 1;28(20):2623-2636. https://doi.org/10.1091/mbc.E17-06-0416. Epub 2017 Aug 9. PMID: 28963439; PMCID: PMC5620371.

Hayakawa K, Esposito E, Wang X, Terasaki Y, Liu Y, Xing C, Ji X, Lo EH. Transfer of mitochondria from astrocytes to neurons after stroke. Nature. 2016 Jul 28;535(7613):551-5. https://doi.org/10.1038/nature18928. Erratum in: Nature. 2016 Sep 14;539(7627):123. https://doi.org/10.1038/nature19805. PMID: 27466127; PMCID: PMC4968589.

Fernandez HR, Varma A, Flowers SA, Rebeck GW. Cancer Chemotherapy Related Cognitive Impairment and the Impact of the Alzheimer's Disease Risk Factor APOE. Cancers (Basel). 2020 Dec 19;12(12):3842. https://doi.org/10.3390/cancers12123842. PMID: 33352780; PMCID: PMC7766535.

Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Am J Psychiatry. 1980 May;137(5):597-601. https://doi.org/10.1176/ajp.137.5.597. PMID: 7369406.

Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, Graham D, Zhou X, Clapp J, Zhai W, Breen E, Carroll JE, Denduluri N, Dilawari A, Extermann M, Isaacs C, Jacobsen PB, Kobayashi LC, Holohan Nudelman K, Root J, Stern RA, Tometich D, Turner R, VanMeter JW, Saykin AJ, Ahles T. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. J Clin Oncol. 2018 Oct 3;36(32):JCO1800140. https://doi.org/10.1200/JCO.18.00140. Epub ahead of print. PMID: 30281396; PMCID: PMC7237199.

Gibson EM, Monje M. Microglia in Cancer Therapy-Related Cognitive Impairment. Trends Neurosci. 2021 Jun;44(6):441-451. https://doi.org/10.1016/j.tins.2021.02.003. Epub 2021 Mar 2. PMID: 33674135; PMCID: PMC8593823.

Dos Santos M, Licaj I, Bellera C, Cany L, Binarelli G, Soubeyran P, Joly F. Cognitive Impairment in Older Cancer Patients Treated with First-Line Chemotherapy. Cancers (Basel). 2021 Dec 7;13(24):6171. https://doi.org/10.3390/cancers13246171. PMID: 34944791; PMCID: PMC8699230.

Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. J Pain Symptom Manage. 2015 Dec;50(6):830-41. https://doi.org/10.1016/j.jpainsymman.2015.06.019. Epub 2015 Sep 5. PMID: 26344551.

Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, Joly F. Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey. Cancer Med. 2019 May;8(5):2654-2663. https://doi.org/10.1002/cam4.2069. Epub 2019 Mar 18. PMID: 30884207; PMCID: PMC6536919.

Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007 Mar;7(3):192-201. https://doi.org/10.1038/nrc2073. PMID: 17318212; PMCID: PMC3329763.

Oboh G, Ogunruku OO. Cyclophosphamide-induced oxidative stress in brain: protective effect of hot short pepper (Capsicum frutescens L. var. abbreviatum). Exp Toxicol Pathol. 2010 May;62(3):227-33. https://doi.org/10.1016/j.etp.2009.03.011. Epub 2009 May 17. PMID: 19447589.

Joshi G, Sultana R, Tangpong J, Cole MP, St Clair DK, Vore M, Estus S, Butterfield DA. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res. 2005 Nov;39(11):1147-54. https://doi.org/10.1080/10715760500143478. PMID: 16298740.

Rajamani R, Muthuvel A, Senthilvelan M, Sheeladevi R. Oxidative stress induced by methotrexate alone and in the presence of methanol in discrete regions of the rodent brain, retina and optic nerve. Toxicol Lett. 2006 Sep 10;165(3):265-73. https://doi.org/10.1016/j.toxlet.2006.05.005. PMID: 16766145.

Zec RF, Trivedi MA. The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev. 2002 Jun;12(2):65-109. https://doi.org/10.1023/a:1016880127635. PMID: 12371603.

Ren X, St Clair DK, Butterfield DA. Dysregulation of cytokine mediated chemotherapy induced cognitive impairment. Pharmacol Res. 2017 Mar;117:267-273. https://doi.org/10.1016/j.phrs.2017.01.001. Epub 2017 Jan 4. PMID: 28063894.

Theodoulou M, Seidman AD. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol. 2003 Dec;30(6):730-9. https://doi.org/10.1053/j.seminoncol.2003.08.024. PMID: 14663774.

Hukovic N, Brown ES. Effects of prescription corticosteroids on mood and memory. Adv Psychosom Med. 2003;24:161-7. https://doi.org/10.1159/000073786. PMID: 14584353.

Brewster KK, Shalev D, Levenson JA. Chemotherapy-Related Cognitive Impairment #342. J Palliat Med. 2017 Dec;20(12):1407-1408. https://doi.org/10.1089/jpm.2017.0524. Epub 2017 Nov 1. PMID: 29091520; PMCID: PMC6913782.

Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone ME, Wesnes KA, Roscoe JA, Morrow GR. The effect of modafinil on cognitive function in breast cancer survivors. Cancer. 2009 Jun 15;115(12):2605-16. https://doi.org/10.1002/cncr.24287. PMID: 19309747; PMCID: PMC2796482.

Lundorff LE, Jønsson BH, Sjøgren P. Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med. 2009 Dec;23(8):731-8. https://doi.org/10.1177/0269216309106872. Epub 2009 Jul 31. PMID: 19648224.

Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005 Mar;30(2):100-7. PMID: 15798785; PMCID: PMC551162.

Boele FW, Douw L, de Groot M, van Thuijl HF, Cleijne W, Heimans JJ, Taphoorn MJ, Reijneveld JC, Klein M. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro Oncol. 2013 Oct;15(10):1420-8. https://doi.org/10.1093/neuonc/not102. Epub 2013 Aug 7. PMID: 23925452; PMCID: PMC3779045.

Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med. 2009 May;12(5):433-9. https://doi.org/10.1089/jpm.2008.0230. PMID: 19416039.

Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, Tannock IF. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer. 2008 Jun;16(6):577-83. https://doi.org/10.1007/s00520-007-0341-9. Epub 2007 Oct 31. PMID: 17972110.

Correa DD, Kryza-Lacombe M, Baser RE, Beal K, DeAngelis LM. Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study. J Neurooncol. 2016 Apr;127(2):313-9. https://doi.org/10.1007/s11060-015-2035-3. Epub 2016 Jan 6. PMID: 26738844; PMCID: PMC4966618.

Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, Rapp SR. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006 Mar 20;24(9):1415-20. https://doi.org/10.1200/JCO.2005.03.3001. PMID: 16549835.

Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, Choucair A, Fox S, Suh JH, Roberge D, Kavadi V, Bentzen SM, Mehta MP, Watkins-Bruner D; Radiation Therapy Oncology Group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013 Oct;15(10):1429-37. https://doi.org/10.1093/neuonc/not114. Epub 2013 Aug 16. PMID: 23956241; PMCID: PMC3779047.

Das A, Ranadive N, Kinra M, Nampoothiri M, Arora D, Mudgal J. An Overview on Chemotherapy-induced Cognitive Impairment and Potential Role of Antidepressants. Curr Neuropharmacol. 2020;18(9):838-851. https://doi.org/10.2174/1570159X18666200221113842. PMID: 32091339; PMCID: PMC7569321.

Boullon L, Abalo R, Llorente-Berzal Á. Cannabinoid Drugs-Related Neuroprotection as a Potential Therapeutic Tool Against Chemotherapy-Induced Cognitive Impairment. Front Pharmacol. 2021 Nov 12;12:734613. https://doi.org/10.3389/fphar.2021.734613. PMID: 34867342; PMCID: PMC8632779.

Kucherer S, Ferguson RJ. Cognitive behavioral therapy for cancer-related cognitive dysfunction. Curr Opin Support Palliat Care. 2017 Mar;11(1):46-51. https://doi.org/10.1097/SPC.0000000000000247. PMID: 27898511; PMCID: PMC5285475.

Ferguson RJ, Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Mott LA. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007 Aug;16(8):772-7. https://doi.org/10.1002/pon.1133. PMID: 17152119; PMCID: PMC3482484.

Miyashita M. Chemotherapy-related cognitive impairment: What we need to know and what we can do. Asia Pac J Oncol Nurs. 2023 Nov 7;11(1):100334. https://doi.org/10.1016/j.apjon.2023.100334. PMID: 38098856; PMCID: PMC10716696.

Lu Y, Bu FQ, Wang F, Liu L, Zhang S, Wang G, Hu XY. Recent advances on the molecular mechanisms of exercise-induced improvements of cognitive dysfunction. Transl Neurodegener. 2023 Feb 27;12(1):9. https://doi.org/10.1186/s40035-023-00341-5. PMID: 36850004; PMCID: PMC9972637.

Orszаghovа Z, Mego M, Chovanec M. Long-Term Cognitive Dysfunction in Cancer Survivors. Front Mol Biosci. 2021 Dec 14;8:770413. https://doi.org/10.3389/fmolb.2021.770413. PMID: 34970595; PMCID: PMC8713760.

MODERN APPROACHES TO NEUROPROTECTION IN TRAUMATIC BRAIN INJURIES, CEREBROVASCULAR DISEASES, AND COGNITIVE IMPAIRMENTS FOLLOWING ANTITUMOR THERAPY

Abstract

Downloads

References

Most read articles by the same author(s)